Publications

Clinical cancer research : an official journal of the American Association for Cancer Research

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

13-07-2026

The Lancet. Oncology

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

01-07-2026

Nature genetics

Insights from three decades of BRCA1/2 modeling in mice.

01-07-2026

Nature communications

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

12-05-2026

NPJ breast cancer

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

06-05-2026

Trends in cancer

FGFR rearrangements: oncogenic drivers and therapeutic targets.

01-05-2026

Science translational medicine

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

18-03-2026

Cancer research

C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

16-03-2026

Oncogene

MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

01-02-2026

Cancer research

Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State.

16-01-2026

Communications medicine

High-throughput spheroid-based assay for functional breast cancer precision medicine facilitated by deep learning.

10-01-2026

Nature

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

01-01-2026

Mammalian genome : official journal of the International Mammalian Genome Society

A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.

10-12-2025

ImmunoHorizons

BRCA1 deficiency leads to aberrant epithelial differentiation in the thymus.

24-11-2025

Communications biology

NAA60 facilitates LRRC8A- and LRRC8D-mediated platinum drug uptake.

06-10-2025

Cancer research

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

02-09-2025

Nature

NASP modulates histone turnover to drive PARP inhibitor resistance.

01-09-2025

Cancer research

Large-scale Characterization of Orthotopic Cell Line-Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness.

15-07-2025

Cancer cell

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets.

14-07-2025

Breast cancer research : BCR

Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.

01-07-2025

Nucleic acids research

TRIP12's role in the governance of DNA polymerase β involvement in DNA damage response and repair.

20-06-2025

JCI insight

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.

09-06-2025

The Journal of clinical investigation

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.

02-06-2025

Cell reports

SRBD1, a highly conserved gene required for chromosome individualization.

22-04-2025

Cancer discovery

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

03-03-2025

Genes & development

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.

07-01-2025

Nature

Mechanisms that clear mutations drive field cancerization in mammary tissue.

01-09-2024

Key Publication

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

Journal of mammary gland biology and neoplasia

Transcriptomic Analysis of Pubertal and Adult Virgin Mouse Mammary Epithelial and Stromal Cell Populations.

25-06-2024

Journal of mammary gland biology and neoplasia

Rat Models of Hormone Receptor-Positive Breast Cancer.

24-06-2024

Nature communications

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.

24-05-2024

The EMBO journal

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

01-03-2024

Breast cancer research : BCR

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.

19-02-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Journal of mammary gland biology and neoplasia

Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.

06-10-2023

STAR protocols

Mouse intraductal modeling of primary ductal carcinoma in situ.

15-09-2023

Molecular cell

Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens.

03-08-2023

Clinical and translational medicine

MIND the translational gap: Preclinical models of ductal carcinoma in situ.

01-08-2023

Journal of mammary gland biology and neoplasia

Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research.

14-07-2023

Science advances

FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks.

02-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

Nature communications

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

07-04-2023

Nature reviews. Cancer

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-02-2023

Nature communications

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.

12-01-2023

Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Key Publication

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Insights from three decades of BRCA1/2 modeling in mice.

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

FGFR rearrangements: oncogenic drivers and therapeutic targets.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State.

High-throughput spheroid-based assay for functional breast cancer precision medicine facilitated by deep learning.

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.

BRCA1 deficiency leads to aberrant epithelial differentiation in the thymus.

NAA60 facilitates LRRC8A- and LRRC8D-mediated platinum drug uptake.

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

NASP modulates histone turnover to drive PARP inhibitor resistance.

Large-scale Characterization of Orthotopic Cell Line-Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness.

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets.

Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma.

TRIP12's role in the governance of DNA polymerase β involvement in DNA damage response and repair.

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.

SRBD1, a highly conserved gene required for chromosome individualization.

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.

Mechanisms that clear mutations drive field cancerization in mammary tissue.

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

Transcriptomic Analysis of Pubertal and Adult Virgin Mouse Mammary Epithelial and Stromal Cell Populations.

Rat Models of Hormone Receptor-Positive Breast Cancer.

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Fourteenth Annual ENBDC Workshop: Methods in Mammary Gland Biology and Breast Cancer.

Mouse intraductal modeling of primary ductal carcinoma in situ.

Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens.

MIND the translational gap: Preclinical models of ductal carcinoma in situ.

Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research.

FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks.

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

This site uses cookies